Detailed information on the current drug pipeline. This report provides insight into the pipeline status of cystic fibrosis drugs by company and by stage as well as a summary of the latest news and developments in this area.

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of bronchospasm drugs by company and by stage as well as a summary of the latest news and developments in this area.

In-depth overview and ten year outlook for currently marketed respiratory drugs, focussing on the Asthma and COPD indications, examining both clinical and commercial factors driving product differentiation and uptake.

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of cough drugs by company and by stage as well as a summary of the latest news and developments in this area.

Idiopathic pulmonary fibrosis is a devastating, relentlessly progressive and lethal disease for which current therapy is minimally effective. However, several promising anti-fibrotic agents, such as Enbrel (etanercept), are now in clinical trials, whic

The respiratory market has experienced below average growth in the last five years (CAGR, 10%) reaching $25.5bn in 2004 in the seven major pharmaceutical markets. Future growth will be essentially flat over the next 10 years (CAGR, 0.6%), estimated to

The large and growing size of the respiratory market, both in terms of patients and current global spend, has encouraged a number of companies to try to enter the sector, as current players attempt to strengthen their portfolios. The top ten companies

Datamonitor expects the global pulmonary arterial hypertension (PAH) market to grow from $636m in 2004 to just over $2 billion by 2014, as new product and formulation launches in the US and a healthy late-stage pipeline drive sales growth. With this in

Identify the latest dealmaking trends in your field

Identify the latest dealmaking trends in your field

Traditionally, the treatment of respiratory infections has largely involved antibiotics from the macrolide class. Advanced Life Sciences’ cethromycin, along with Sanofi-Aventis’ Ketek, is a ketolide, a second-generation class of macrolides

In the US, approximately 88 million people are diagnosed with a respiratory tract infection in an average year. Of these, a total of 66 million patients suffer from one of the three major diagnoses: acute bacterial sinusitis (ABS), acute exacerbation o

RSV mostly causes upper respiratory tract infections (URTI), resulting in the common cold. However, in certain risk groups, RSV can cause more severe lower respiratory tract infections (LRTI) leading to bronchiolitis. These risk groups include elderly